These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

149 related items for PubMed ID: 16019449

  • 1. Coagulopathy, following medical therapy, for carcinoma of the prostate.
    Bern MM.
    Hematology; 2005 Feb; 10(1):65-8. PubMed ID: 16019449
    [Abstract] [Full Text] [Related]

  • 2. Coagulopathy in prostate cancer.
    de la Fouchardière C, Flechon A, Droz JP.
    Neth J Med; 2003 Nov; 61(11):347-54. PubMed ID: 14768717
    [Abstract] [Full Text] [Related]

  • 3. Ketoconazole and Flutamide in the treatment of disseminated intravascular clotting from prostate cancer: a case report and review.
    Chakrapee-Sirisuk S, Amornpichetkul K, Visudhiphan S, Sangruchi T, Srimuninnimit V, Sinlarat P.
    J Med Assoc Thai; 2001 Oct; 84(10):1495-501. PubMed ID: 11804262
    [Abstract] [Full Text] [Related]

  • 4. [Metastatic prostate cancer complicated with chronic disseminated intravascular coagulopathy causing acute renal failure, mimicking thrombotic thrombocytopenic purpura and hemolytic uremic syndrome: pathomechanism, differential diagnosis and therapy related to a case].
    Deme D, Ragán M, Kalmár K, Kovács L, Varga E, Varga T, Rakonczai E.
    Magy Onkol; 2010 Dec; 54(4):351-7. PubMed ID: 21163766
    [Abstract] [Full Text] [Related]

  • 5. Disseminated intravascular coagulation with excessive fibrinolysis in prostate cancer: a case series and review of the literature.
    Hyman DM, Soff GA, Kampel LJ.
    Oncology; 2011 Dec; 81(2):119-25. PubMed ID: 21986538
    [Abstract] [Full Text] [Related]

  • 6. Disseminated intravascular coagulation and excessive fibrinolysis in a patient with metastatic prostate cancer. Response to epsilon-aminocaproic acid.
    Cooper DL, Sandler AB, Wilson LD, Duffy TP.
    Cancer; 1992 Aug 01; 70(3):656-8. PubMed ID: 1623480
    [Abstract] [Full Text] [Related]

  • 7. [Prostatic adenocarcinoma revealed by disseminated intravascular coagulation and fibrinolysis].
    Rabii R, Salomon L, Hodznek A, Saint F, Cicco A, Chopin DK, Abbou CC.
    Ann Urol (Paris); 2002 Jul 01; 36(4):269-71. PubMed ID: 12162193
    [Abstract] [Full Text] [Related]

  • 8. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma.
    Crawford ED, Eisenberger MA, McLeod DG, Spaulding JT, Benson R, Dorr FA, Blumenstein BA, Davis MA, Goodman PJ.
    N Engl J Med; 1989 Aug 17; 321(7):419-24. PubMed ID: 2503724
    [Abstract] [Full Text] [Related]

  • 9. [Haematological complications of prostatic cancer: 2 cases, one revealing the neoplasia].
    Albiges L, Cottu PH, Cojean-Zelek I, Raymond F, Zerkak D, Aerts J, Ziza JM.
    Rev Med Interne; 2007 Mar 17; 28(3):176-8. PubMed ID: 17229492
    [Abstract] [Full Text] [Related]

  • 10. Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss.
    Preston DM, Torréns JI, Harding P, Howard RS, Duncan WE, McLeod DG.
    Prostate Cancer Prostatic Dis; 2002 Mar 17; 5(4):304-10. PubMed ID: 12627216
    [Abstract] [Full Text] [Related]

  • 11. [Consumption coagulopathy disclosing prostatic cancer].
    Vantaux P, Schneider P, Le Coz S, Villers A.
    Prog Urol; 2001 Feb 17; 11(1):68-9. PubMed ID: 11296649
    [Abstract] [Full Text] [Related]

  • 12. Leuprolide with flutamide for complete androgen ablation: therapeutic alternative for advanced prostatic cancer (stage D2).
    Chime-Udeh E.
    Conn Med; 1991 Sep 17; 55(9):526-8. PubMed ID: 1748007
    [No Abstract] [Full Text] [Related]

  • 13. Use of low molecular weight heparin and aminocaproic acid in chronic DIC associated with prostate cancer--a case report.
    Shirai K, Chaudhary UB.
    ScientificWorldJournal; 2007 Feb 02; 7():753-5. PubMed ID: 17619757
    [Abstract] [Full Text] [Related]

  • 14. [Disseminated intravascular coagulation syndrome with secondary fibrinolysis activation in prostatic carcinoma].
    Iwan-Zietek I, Zietek Z, Kotschy M, Tyloch F, Szymański A.
    Pol Tyg Lek; 1996 Feb 02; 51(6-9):100-1. PubMed ID: 8756745
    [Abstract] [Full Text] [Related]

  • 15. Discovery of a pituitary adenoma following treatment with a gonadotropin-releasing hormone agonist in a patient with prostate cancer.
    Massoud W, Paparel P, Lopez JG, Perrin P, Daumont M, Ruffion A.
    Int J Urol; 2006 Jan 02; 13(1):87-8. PubMed ID: 16448441
    [Abstract] [Full Text] [Related]

  • 16. Effects of flutamide as a second-line agent for maximum androgen blockade of hormone refractory prostate cancer.
    Nishimura K, Arichi N, Tokugawa S, Yoshioka I, Kishikawa H, Ichikawa Y.
    Int J Urol; 2007 Mar 02; 14(3):264-7. PubMed ID: 17430272
    [Abstract] [Full Text] [Related]

  • 17. Intermittent androgen suppression for locally advanced and metastatic prostate cancer: preliminary report of a prospective multicenter study.
    Sato N, Akakura K, Isaka S, Nakatsu H, Tanaka M, Ito H, Masai M, Chiba Prostate Study Group.
    Urology; 2004 Aug 02; 64(2):341-5. PubMed ID: 15302491
    [Abstract] [Full Text] [Related]

  • 18. Disseminated intravascular coagulation secondary to metastatic prostate cancer: case report and review of the literature.
    Pinto F, Brescia A, Sacco E, Volpe A, Gardi M, Gulino G, Bassi P.
    Arch Ital Urol Androl; 2009 Dec 02; 81(4):212-4. PubMed ID: 20608143
    [Abstract] [Full Text] [Related]

  • 19. Carcinoma of the prostate. Treating disease that has metastasized.
    Baum N, Brown P.
    Postgrad Med; 1990 Nov 01; 88(6):77-84. PubMed ID: 1700405
    [Abstract] [Full Text] [Related]

  • 20. [Disseminated intravascular coagulation syndrome (D.I.C.) and carcinoma of the prostate (author's transl)].
    Becopoulos T, Kranides A, Mandalaki-Yianitsiotis T, Louizou K, Panagiotopoulou E, Dimopoulos C.
    J Urol (Paris); 1980 Nov 01; 86(6):467-70. PubMed ID: 6160184
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.